Reports


Global Systemic Lupus Erythematosus (SLE) Drugs Market Research Report 2019 (Includes Business Impact of COVID-19)

  • TBI796086
  • May 03, 2019
  • Global
  • 97 pages
  • QY Market Research
                                              "The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Systemic Lupus Erythematosus (SLE) Drugs market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Systemic Lupus Erythematosus (SLE) Drugs market."
SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market. Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

The global Systemic Lupus Erythematosus (SLE) Drugs market is valued at 170 million US$ in 2018 is expected to reach 280 million US$ by the end of 2025, growing at a CAGR of 6.8% during 2019-2025.
This report focuses on Systemic Lupus Erythematosus (SLE) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Systemic Lupus Erythematosus (SLE) Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Anthera Pharmaceuticals
    GSK
    ImmuPharma
    Johnson & Johnson
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Corticosteroids
    Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    Anti-Inflammatories
    Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Antimalarials
    BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
    Immunosuppressive Agents/Immune Modulators
    Anticoagulants

Segment by Application
    Intravenous
    Sub-Cutaneous
    Oral
    Topical
 

Table of Contents

Executive Summary
1 Systemic Lupus Erythematosus (SLE) Drugs Market Overview
    1.1 Product Overview and Scope of Systemic Lupus Erythematosus (SLE) Drugs
    1.2 Systemic Lupus Erythematosus (SLE) Drugs Segment by Type
        1.2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Production Growth Rate Comparison by Type (2014-2025)
        1.2.2 Corticosteroids
        1.2.3 Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
        1.2.4 Anti-Inflammatories
        1.2.5 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
        1.2.6 Antimalarials
        1.2.7 BLyS-Specific Inhibitors or Monoclonal Antibodies (MAbS)
        1.2.8 Immunosuppressive Agents/Immune Modulators
        1.2.9 Anticoagulants
    1.3 Systemic Lupus Erythematosus (SLE) Drugs Segment by Application
        1.3.1 Systemic Lupus Erythematosus (SLE) Drugs Consumption Comparison by Application (2014-2025)
        1.3.2 Intravenous
        1.3.3 Sub-Cutaneous
        1.3.4 Oral
        1.3.5 Topical
    1.4 Global Systemic Lupus Erythematosus (SLE) Drugs Market by Region
        1.4.1 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size Region
        1.4.2 North America Status and Prospect (2014-2025)
        1.4.3 Europe Status and Prospect (2014-2025)
        1.4.4 China Status and Prospect (2014-2025)
        1.4.5 Japan Status and Prospect (2014-2025)
    1.5 Global Systemic Lupus Erythematosus (SLE) Drugs Market Size
        1.5.1 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue (2014-2025)
        1.5.2 Global Systemic Lupus Erythematosus (SLE) Drugs Production (2014-2025)

2 Global Systemic Lupus Erythematosus (SLE) Drugs Market Competition by Manufacturers
    2.1 Global Systemic Lupus Erythematosus (SLE) Drugs Production Market Share by Manufacturers (2014-2019)
    2.2 Global Systemic Lupus Erythematosus (SLE) Drugs Revenue Share by Manufacturers (2014-2019)
    2.3 Global Systemic Lupus Erythematosus (SLE) Drugs Average Price by Manufacturers (2014-2019)
    2.4 Manufacturers Systemic Lupus Erythematosus (SLE) Drugs Production Sites, Area Served, Product Types
    2.5 Systemic Lupus Erythematosus (SLE) Drugs Market Competitive Situation and Trends
        2.5.1 Systemic Lupus Erythematosus (SLE) Drugs Market Concentration Rate
        2.5.2 Systemic Lupus Erythematosus (SLE) ...
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form